Bupropion as an aid to smoking cesstation: A review of real-life effectiveness

S. Holmes, N. Zwar, C. A. Jiménez-Ruiz, P. J. Ryan, D. Browning, L. Bergmann, J. Andrew Johnston

Research output: Contribution to journalReview articleResearchpeer-review

27 Citations (Scopus)

Abstract

Clinical trials rigorously demonstrate the efficacy of new products and justify their marketing. However, it is only after use in real-life settings that the clinical value (effectiveness) of a new treatment is fully known. The purpose of this review was to summarise the effectiveness data for bupropion SR as an aid to smoking cessation. Available reports of effectiveness data for bupropion SR were obtained from the literature, presentations at smoking cessation meetings and from the manufacturer. Twelve sources of effectiveness data were found and included clinical practice trials, observational studies/surveys, motivational support programme results and employer-based cessation programme results. The 6-month point prevalence smoking cessation rates ranged from 25 to 49%. There is a growing body of evidence supporting the effectiveness of bupropion SR as an aid to smoking cessation. Real-life quit rates for bupropion SR are similar to those seen in the original clinical trial programme.

Original languageEnglish
Pages (from-to)285-291
Number of pages7
JournalInternational Journal of Clinical Practice
Volume58
Issue number3
DOIs
Publication statusPublished - 1 Mar 2004
Externally publishedYes

Fingerprint

Bupropion
Smoking Cessation
Smoking
Clinical Trials
Information Storage and Retrieval
Marketing
Observational Studies

Cite this

Holmes, S., Zwar, N., Jiménez-Ruiz, C. A., Ryan, P. J., Browning, D., Bergmann, L., & Johnston, J. A. (2004). Bupropion as an aid to smoking cesstation: A review of real-life effectiveness. International Journal of Clinical Practice, 58(3), 285-291. https://doi.org/10.1111/j.1368-5031.2004.00153.x
Holmes, S. ; Zwar, N. ; Jiménez-Ruiz, C. A. ; Ryan, P. J. ; Browning, D. ; Bergmann, L. ; Johnston, J. Andrew. / Bupropion as an aid to smoking cesstation : A review of real-life effectiveness. In: International Journal of Clinical Practice. 2004 ; Vol. 58, No. 3. pp. 285-291.
@article{74a5f3e7e7614055be2f4c7c92b3033a,
title = "Bupropion as an aid to smoking cesstation: A review of real-life effectiveness",
abstract = "Clinical trials rigorously demonstrate the efficacy of new products and justify their marketing. However, it is only after use in real-life settings that the clinical value (effectiveness) of a new treatment is fully known. The purpose of this review was to summarise the effectiveness data for bupropion SR as an aid to smoking cessation. Available reports of effectiveness data for bupropion SR were obtained from the literature, presentations at smoking cessation meetings and from the manufacturer. Twelve sources of effectiveness data were found and included clinical practice trials, observational studies/surveys, motivational support programme results and employer-based cessation programme results. The 6-month point prevalence smoking cessation rates ranged from 25 to 49{\%}. There is a growing body of evidence supporting the effectiveness of bupropion SR as an aid to smoking cessation. Real-life quit rates for bupropion SR are similar to those seen in the original clinical trial programme.",
author = "S. Holmes and N. Zwar and Jim{\'e}nez-Ruiz, {C. A.} and Ryan, {P. J.} and D. Browning and L. Bergmann and Johnston, {J. Andrew}",
year = "2004",
month = "3",
day = "1",
doi = "10.1111/j.1368-5031.2004.00153.x",
language = "English",
volume = "58",
pages = "285--291",
journal = "British Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "3",

}

Holmes, S, Zwar, N, Jiménez-Ruiz, CA, Ryan, PJ, Browning, D, Bergmann, L & Johnston, JA 2004, 'Bupropion as an aid to smoking cesstation: A review of real-life effectiveness' International Journal of Clinical Practice, vol. 58, no. 3, pp. 285-291. https://doi.org/10.1111/j.1368-5031.2004.00153.x

Bupropion as an aid to smoking cesstation : A review of real-life effectiveness. / Holmes, S.; Zwar, N.; Jiménez-Ruiz, C. A.; Ryan, P. J.; Browning, D.; Bergmann, L.; Johnston, J. Andrew.

In: International Journal of Clinical Practice, Vol. 58, No. 3, 01.03.2004, p. 285-291.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Bupropion as an aid to smoking cesstation

T2 - A review of real-life effectiveness

AU - Holmes, S.

AU - Zwar, N.

AU - Jiménez-Ruiz, C. A.

AU - Ryan, P. J.

AU - Browning, D.

AU - Bergmann, L.

AU - Johnston, J. Andrew

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Clinical trials rigorously demonstrate the efficacy of new products and justify their marketing. However, it is only after use in real-life settings that the clinical value (effectiveness) of a new treatment is fully known. The purpose of this review was to summarise the effectiveness data for bupropion SR as an aid to smoking cessation. Available reports of effectiveness data for bupropion SR were obtained from the literature, presentations at smoking cessation meetings and from the manufacturer. Twelve sources of effectiveness data were found and included clinical practice trials, observational studies/surveys, motivational support programme results and employer-based cessation programme results. The 6-month point prevalence smoking cessation rates ranged from 25 to 49%. There is a growing body of evidence supporting the effectiveness of bupropion SR as an aid to smoking cessation. Real-life quit rates for bupropion SR are similar to those seen in the original clinical trial programme.

AB - Clinical trials rigorously demonstrate the efficacy of new products and justify their marketing. However, it is only after use in real-life settings that the clinical value (effectiveness) of a new treatment is fully known. The purpose of this review was to summarise the effectiveness data for bupropion SR as an aid to smoking cessation. Available reports of effectiveness data for bupropion SR were obtained from the literature, presentations at smoking cessation meetings and from the manufacturer. Twelve sources of effectiveness data were found and included clinical practice trials, observational studies/surveys, motivational support programme results and employer-based cessation programme results. The 6-month point prevalence smoking cessation rates ranged from 25 to 49%. There is a growing body of evidence supporting the effectiveness of bupropion SR as an aid to smoking cessation. Real-life quit rates for bupropion SR are similar to those seen in the original clinical trial programme.

UR - http://www.scopus.com/inward/record.url?scp=2342432925&partnerID=8YFLogxK

U2 - 10.1111/j.1368-5031.2004.00153.x

DO - 10.1111/j.1368-5031.2004.00153.x

M3 - Review article

VL - 58

SP - 285

EP - 291

JO - British Journal of Clinical Practice

JF - British Journal of Clinical Practice

SN - 1368-5031

IS - 3

ER -